Endometriosis Treatment Market Size & Share 2026-2035

Endometriosis Treatment Market Size

The global endometriosis treatment market was estimated at USD 1.9 billion in 2025. The market is expected to grow from USD 2.1 billion in 2026 to USD 6.5 billion in 2035, at a CAGR of 13.4% during the analysis period, as per the latest report published by Global Market Insights, Inc.

According to the World Health Organization (WHO), globally, 190 million (10%) women of reproductive age are affected by endometriosis, equating to a large patient population requiring medical intervention. This significant increase in patient population, coupled with growing awareness about the condition and its impact on fertility among patients, is supporting the market’s growth.

Endometriosis treatment refers to the medical and supportive interventions used to relieve pain, control the growth of endometrial-like tissue outside the uterus, and preserve or restore fertility. Common medical treatments include painkillers, hormonal treatment with progestins, combined oral contraceptives, and GnRH modulators to inhibit menstruation and inflammation. Key players such as AbbVie, Bayer, Pfizer, AstraZeneca, and Gedeon Richter lead the market with their wide product portfolio and robust R&D. These players influence market growth through innovative hormonal therapies, non-hormonal pain management alternatives, the development of next-generation oral GnRH antagonists, and the broadening of treatment indications.

The endometriosis treatment market witnessed steady growth, growing from USD 1.4 billion in 2022 to USD 1.7 billion in 2024, driven by rising diagnosis rates, greater awareness of women's health conditions, and the launch of next-generation therapeutic drugs. The market witnessed a significant transition from dependence on conventional hormonal therapies to embracing next-generation oral GnRH antagonists with better symptom control and more convenient dosing, along with fewer long-term side effects. Pharmaceutical firms increased their R&D spend, resulting in successive product launches and widening approvals in core markets. On the reimbursement front, supportive policies in developed economies, along with increasing advocacy and education campaigns, reduced underdiagnosis and promoted earlier treatment. This convergence of innovation, improved access, and changing clinical guidelines fueled steady market growth.
 

Further, the growing emphasis on women’s health has led to increased healthcare expenditure and efforts to improve women’s health. This has resulted in improved accessibility to endometriosis diagnostics and treatment. For instance, the Endometriosis Association conducts the Teen Outreach Program that aims to educate teen girls about the importance of early diagnosis and timely interventions for endometriosis. To date, the organization has distributed 2,577 Teen Outreach educational packages in 34 states. Such initiatives by health organizations and pharmaceutical companies are encouraging more women to seek timely treatment. Additionally, advancements in drug development, minimally invasive therapies, and the introduction of hormone therapies are further expected to propel the growth of this market.

Endometriosis is a condition in which the growth of tissue similar to the lining inside the uterus occurs outside the uterus, resulting in pain, mainly during menstruation, and can cause severe issues such as infertility. Treatment aims to manage symptoms and slowing the disease progression. Common treatment approaches, such as pain management drugs including non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies, are used.

Endometriosis Treatment Market Trends

• The market is experiencing significant growth, driven by several key trends that are shaping its trajectory. One of the primary trends is the increasing prevalence of endometriosis and awareness about the condition through government and health organizations.
• For instance, in the U.S., 6.5 million women and girls as young as eight years old suffer from endometriosis, and the global prevalence of the disease reaching approximately 89 million. Thus, the growing prevalence of the disease is leading to an increasing adoption of endometriosis treatment.
• Additionally, due to increased prevalence and awareness, there is a rise in healthcare expenditure and growing investments in women’s health, thus fostering the market’s growth. For instance, in February 2025, the Federal Government announced an investment of USD 573 million for addressing the healthcare needs of women living with endometriosis and chronic pelvic pain in Australia.
• Further, there is an increasing shift towards non-invasive and patient-centric solutions. The patients are not only seeking effective treatment but are also looking for convenient and less invasive treatment options, thus driving the market growth.
• Furthermore, oral GnRH antagonists are gaining popularity on account of their rapid onset of action, dose flexibility, and enhanced safety profile over traditional injectables. Their ease of use and reversibility make them ideal for long-term treatment, while combination products with low-dose estrogen are widening their application among a wider patient population. With strong clinical backing and strategic marketing, such agents are witnessing accelerated uptake in developed and emerging markets.
• Another key trend in the endometriosis treatment industry is a shift towards non-hormonal drugs, with patients and clinicians looking for treatments that address pain and inflammation without compromising hormonal status. Market players are increasingly focusing on the development of immune-modulating and neuroinflammation-targeting medications as a means of offering sustainable symptom control to women who cannot tolerate or prefer not to take hormonal therapies. Such key developments are shaping the market.

Endometriosis Treatment Market Analysis

Based on the disease type, the endometriosis treatment market is segmented into superficial peritoneal endometriosis, ovarian endometriomas, deep infiltrating endometriosis, and other disease types. The superficial peritoneal endometriosis segment dominated the global market with 48.1% market share in 2025. On the other hand, the ovarian endometriomas segment was valued at USD 528.4 million in 2025 and is anticipated to grow at a CAGR of 13.5% over the analysis period. Ovarian endometriomas hold a considerable market share in the treatment market for endometriosis, as they are very common and have major implications on fertility, pain, and quality of life. Their complicated nature usually calls for long-term medical care, driving sustained demand for drug-based therapies.

• Superficial peritoneal endometriosis is the most common form of the disease and is characterized by lesions. For instance, as per an article published by National Institutes of Health, approximately 80% of women affected by endometriosis have superficial lesions. It affects a large proportion of women diagnosed with endometriosis, making it the dominant disease type in this market.
• It is more easily diagnosed as it occurs on the peritoneal surface compared to deeper infiltrating forms. This early diagnosis of the superficial peritoneal endometriosis facilitates timely intervention.
• Additionally, for managing superficial peritoneal endometriosis, a broader range of treatment approaches is available, including pain management and hormonal therapies. Thus, the availability of a variety of treatment options facilitates adoption.

Based on the treatment type, the endometriosis treatment market is categorized into hormone therapy and pain medication. The hormone therapy segment was valued at USD 1.5 billion in 2025.

• Oral contraceptives, GnRH agonists, and progestins are hormone therapies that are widely used as first-line treatments for managing symptoms like pelvic pain, heavy menstrual bleeding, and dysmenorrhea.
• Additionally, their proven efficacy, ease of administration, and increased patient preference contribute to the growing demand for hormone therapy in the endometriosis market.
• Moreover, continuous research and development have led to advancements in hormonal treatments, such as GnRH antagonists with reduced side effects and selective progesterone receptor modulators, which are broadening the therapeutic options and fuelling market growth.
• For instance, the launch of Orilissa for managing moderate to severe pain in endometriosis is the first oral endometriosis medication that uses a gonadotropin-releasing hormone (GnRH) antagonist. Such product approvals are further expanding the availability of hormone therapies.
• The pain medication segment is anticipated to witness stable growth, growing at a CAGR of 11.6% over the forecast period.
• Pain medications are widely adopted for the management of endometriosis due to their ability to offer fast relief from symptoms and their universal availability for chronic pelvic pain management. Their role as first-line therapy before or alongside hormonal treatments supports their strong market presence.

Based on the drug class, the endometriosis treatment market is categorized into gonadotropin-releasing hormone, NSAIDs, oral contraceptives, and other drug classes. The gonadotropin-releasing hormone segment is expected to grow at 13.8% CAGR over the analysis period.

• The gonadotropin-releasing hormone (GnRH) segment commands a high market share in the market because of its established effectiveness in reducing estrogen production, thereby alleviating symptoms such as chronic pelvic pain and heavy menstrual bleeding.
• These treatments come in agonist and antagonist forms and are commonly prescribed as first-line or adjunct therapy, especially in patients who do not respond to conventional pain management.
• These drugs benefit from a strong clinical track record, diverse product availability, and continuous improvements in formulations that minimize side effects.
• The oral contraceptive segment holds the second-largest market share in the endometriosis treatment industry, owing to its dual advantage of symptom relief and disease prevention.
• These pills regulate menstrual cycles, decrease menstrual flow, and reduce estrogen levels, thus alleviating pain and inflammation of endometriosis.
• Their wide accessibility, cost-effectiveness, and familiarity among both patients and clinicians contribute to strong adoption rates.

Based on the route of administration, the endometriosis treatment market is bifurcated into oral, injectable, and other routes of administration. The oral segment dominated the market in 2025 with a market share of 64.9% and is projected to reach USD 4.1 billion by 2035.

• Oral treatments, including oral contraceptives, progestins, and NSAIDs are commonly used for managing endometriosis symptoms such as pain and heavy bleeding owing to their ease of administration.
• Additionally, the growing availability of oral treatments like GnRH antagonists, which are more effective and have fewer side effects, is further boosting demand.
• Compared to other treatments, oral therapies are more cost-effective, making them easier to access in both developed and developing countries.
• Moreover, increased awareness of endometriosis, early diagnosis, and the preference for non-invasive treatments are expected to significantly drive the growth of the oral segment.

Based on the distribution channel, the endometriosis treatment market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the highest market share of 51.6% in 2025.

• Hospital pharmacies hold a dominant share as key distribution channels in the market due to their central role in providing immediate access to medications following diagnosis or surgical intervention.
• These pharmacies provide access to newly launched treatments that other retail pharmacies may not yet have procured. They provide the most advanced therapeutic options for patients, thereby holding a dominant share in the endometriosis treatment industry.
• The online pharmacies segment, on the other hand, is anticipated to witness high growth in the market, growing at a CAGR of 14.5% between 2026 - 2035. These platforms provide patients with convenient access to therapies of all types, including hormonal therapy, painkillers, and combined treatment at reasonable prices.
• Additionally, growing internet penetration, easy-to-use mobile apps, and support by governments for e-pharmacy services in most countries are also driving adoption further, making online a rapidly emerging distribution channel.

North America Endometriosis Treatment Market

North America dominated the market in 2025, holding a market share of 42.8%, driven by a high prevalence of the disease, strong healthcare infrastructure, and increasing adoption of fertility-preserving therapies.

• According to the Office on Women’s Health, endometriosis affects over 11% of women aged 15–44 in the U.S., particularly those in their 30s and 40s.
• The NIH estimates the incidence to be 5–15% among reproductive-age women and 2–5% in postmenopausal women in both the U.S. and Canada. Such a high incidence of endometriosis in the region drives the demand for effective treatments.
• Further, the region benefits from a strong clinical and commercial ecosystem, with major pharmaceutical firms and academic institutions accelerating trials and therapeutic developments.

The U.S. endometriosis treatment market size reached USD 719 million in 2025 from USD 645.4 million in 2024.

• In the U.S., heightened awareness and early diagnosis, spurred by educational initiatives such as the Teen Outreach Program and the ENPOWR Project, are set to drive growth in the endometriosis treatment industry.
• Further, the growing prevalence of endometriosis is driving the demand for endometriosis treatment. For instance, according to the Endometriosis Foundation of America, approximately 1 in 10 women in the U.S. are affected by endometriosis during their reproductive years, highlighting the significant need for effective treatments.
• This program helps reduce stigma and promote positive treatment behaviours, which results in earlier treatments and an increased treatment demand.
• Furthermore, improvements in treatment, emphasis on reproductive health safeguarding, and better access to healthcare services have also enhanced market expansion.

Europe Endometriosis Treatment Market

The Europe market was valued at USD 546.4 million in 2025 and is projected to reach USD 1.8 billion by 2035, supported by improved awareness, earlier diagnosis, and access to specialized care.

• Universal healthcare systems across the region enable timely access to first-line treatments, such as oral contraceptives, NSAIDs, and progestins.
• The region’s robust R&D landscape is attracting pharma investments and accelerating the development of targeted therapies.
• Moreover, the rising demand for treatment in patients is fuelled by the increased focus on women’s health, which further accelerates spending in research and patient care treatment.

Germany endometriosis treatment market is expected to experience high growth during the forecast period.

• According to the data from the German Hospital Statistics, in 2022, there were around 32,000 endometriotic stays recorded in German hospitals, which comes to about 0.8 cases per 1,000 residents.
• This growing number of hospitalizations shows an increasing awareness alongside the diagnosis of the disease, which in turn increases the need for better treatment options.
• The market is further expected to grow due to the well-developed healthcare system in Germany that provides patients with various treatment options, as well as the patients being able to receive effective and advanced care.
• The growth is further driven by Germany’s leadership in medical innovation and research, which has led to the emergence of new treatment options for endometriosis.

Asia Pacific Endometriosis Treatment Market

The Asia Pacific region is expected to witness high growth in the market, growing at a CAGR of 13.9% over the analysis years.

• A high concentration of reproductive-age women, over 140 million with unmet contraceptive needs, according to UNFPA, is fueling treatment demand.
• Additionally, rising awareness, improved access to gynecological care, and enhanced public health outreach in countries like China, India, and Japan are boosting diagnosis rates.

India endometriosis treatment industry is projected to experience substantial growth throughout the forecast period.

• According to a research article published by the National Institutes of Health, endometriosis is estimated to affect 10% of reproductive-age women, which is approximately 42 million women in India.
• Furthermore, the availability of advanced diagnostic techniques and growing healthcare accessibility in the country are leading to an increased number of patients diagnosed with endometriosis. This rise in diagnosis is contributing to increased demand for medical interventions.
• Thus, India’s high prevalence of endometriosis, together with increased spending on healthcare and growth in scientific research, creates a high demand for effective treatments, thereby fostering market growth.

Latin America Endometriosis Treatment Market

The Latin America market projected to witness considerable growth over the analysis period.

• Growing understanding of endometriosis by health practitioners and the general population has resulted in higher diagnosis rates in the region.
• More women becoming aware of the consequences and manifestations of endometriosis translates to them being more willing to receive medical care, fuelling market growth.
• Further, rapid infrastructure development in countries such as Brazil and Mexico and growing access to healthcare will drive treatment adoption rates, thereby boosting regional market growth.

Middle East & Africa Endometriosis Treatment Market

Middle East & Africa market was valued at USD 44.6 million in 2025, with growth constrained by underreporting, limited diagnostic capabilities, and cultural stigma.

• The endometriosis treatment industry in the Middle East and Africa (MEA) is in its nascent stages, with limited awareness and access to healthcare in many regions.
• However, countries such as Saudi Arabia, the UAE, and South Africa are seeing gradual growth due to rising awareness, government healthcare initiatives, and improving healthcare infrastructure.

Endometriosis Treatment Market Share

The market is characterized by a diverse competitive landscape driven by various factors, including technological advancements, patient demand for effective treatments, and increasing awareness of the disease. The top 5 players operating in this market include AstraZeneca, Bayer, Gedeon Richter, Pfizer, and AbbVie, which account for ~62% of the market. Leading pharmaceutical companies dominate the market due to their comprehensive product portfolios, established brand recognition, and large-scale distribution networks. These companies hold significant market share by offering a range of hormonal therapies, pain management options, and non-hormonal treatments.

Furthermore, the market is experiencing growth due to rising global awareness of endometriosis, improved access to healthcare, and advancements in diagnostic technologies. The growing emphasis on personalized treatment solutions and digital health innovations further fuels the market’s expansion, creating opportunities for both large and small players in the industry.

Endometriosis Treatment Market Companies

Few of the prominent players operating in the endometriosis treatment industry include:

• AbbVie
• AstraZeneca
• Bayer
• Debiopharm
• Gedeon Richter
• Kissei Pharmaceutical
• Pfizer
• Sanofi
• Teva Pharmaceutical
• Zydus

• AbbVie

AbbVie maintains a leading position in the endometriosis treatment market through its established expertise in hormone-based therapies and sustained investment in clinical research. Its product portfolio includes elagolix (marketed as Orilissa), a GnRH receptor antagonist approved for the management of moderate to severe endometriosis-associated pain. AbbVie’s approach combines therapeutic development with a robust clinical evidence base to address both symptom relief and disease progression. The company continues to advance combination therapies while exploring the potential of next-generation formulations that minimize hypoestrogenic side effects while maintaining efficacy.

• Pfizer

Pfizer maintains a significant presence in the endometriosis treatment landscape by leveraging its longstanding experience in reproductive health, hormone modulation, and chronic disease management. The company’s once-daily combination therapy, MYFEMBREE (relugolix, estradiol, norethindrone acetate), developed in partnership with Myovant Sciences, received U.S. FDA approval in August 2022, thereby expanding Pfizer’s footprint in non-surgical treatment pathways for endometriosis-related pain. The approval of MYFEMBREE reflects Pfizer’s ongoing commitment to developing scalable, patient-adaptable treatment options aimed at reducing the dependency on invasive interventions.

Endometriosis Treatment Industry News

• In June 2024, Kissei Pharmaceutical signed a licensing agreement with JW Pharmaceutical Corporation for the development and commercialization of linzagolix in Korea. JWP took charge of clinical development and sales, while Kissei received upfront, milestone, and royalty payments. This agreement strengthened Kissei’s global presence and contributed to its fiscal 2025 earnings forecast.
• In August 2022, U.S. FDA approved MYFEMBREE for once-daily treatment of moderate to severe pain associated with endometriosis in premenopausal women. This regulatory milestone expanded MYFEMBREE’s market potential and strengthened both companies’ portfolios in women’s health.
• In February 2022, ObsEva entered into a licensing agreement with Theramex for the commercialization of linzagolix in markets outside the U.S., Canada, and Asia. Theramex gained the right to market the drug, while ObsEva secured upfront, milestone, and royalty payments. The drug, originally discovered by Kissei Pharmaceutical, expanded its global reach through this partnership and supported ObsEva’s revenue potential.
• In October 2021, Debiopharm and Dexa Medica launched Triptorelin in Indonesia for treating gynecological disorders, especially endometriosis. The drug, marketed as Pamorelin, is a GnRH agonist that reduces pain by lowering estrogen levels. This collaboration expanded treatment options for endometriosis in Southeast Asia.
• In July 2021, Ryeqo (relugolix/estradiol/norethisterone acetate) received marketing authorization from the European Commission for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. This approval followed a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on May 21, 2021.

The endometriosis treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Superficial peritoneal endometriosis
• Ovarian endometriomas
• Deep infiltrating endometriosis
• Other disease types

Market, By Treatment Type

• Hormone therapy
• Pain medication

Market, By Drug Class

• Gonadotropin-releasing hormone
• NSAIDs
• Oral contraceptive
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable
• Other routes of administration

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE